3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole has been researched along with Pre-Eclampsia in 2 studies
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source
lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.
Pre-Eclampsia: A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Preeclampsia is a serious complication of pregnancy with no medical treatment." | 1.42 | YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia. ( Brownfoot, FC; Cannon, P; Hannan, NJ; Hastie, R; Kaitu'u-Lino, TJ; Tong, S; Tuohey, L, 2015) |
| "We conclude that in preeclampsia, the decrease of relaxation responses and the decrease of cGMP content could be due to the reduction in stimulation of sGC and the decrease in cGMP levels." | 1.39 | Investigation of the role of the NO-cGMP pathway on YC-1 and DEA/NO effects on thoracic aorta smooth muscle responses in a rat preeclampsia model. ( Bagcivan, I; Karadas, B; Parlak, M; Temiz, TK; Turgut, B; Turgut, NH, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Turgut, NH | 1 |
| Temiz, TK | 1 |
| Turgut, B | 1 |
| Karadas, B | 1 |
| Parlak, M | 1 |
| Bagcivan, I | 1 |
| Brownfoot, FC | 1 |
| Tong, S | 1 |
| Hannan, NJ | 1 |
| Hastie, R | 1 |
| Cannon, P | 1 |
| Tuohey, L | 1 |
| Kaitu'u-Lino, TJ | 1 |
2 other studies available for 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Pre-Eclampsia
| Article | Year |
|---|---|
Investigation of the role of the NO-cGMP pathway on YC-1 and DEA/NO effects on thoracic aorta smooth muscle responses in a rat preeclampsia model.
Topics: Animals; Aorta, Thoracic; Blood Pressure; Cyclic GMP; Disease Models, Animal; Dose-Response Relation | 2013 |
YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia.
Topics: Adult; Antigens, CD; Endoglin; Female; Human Umbilical Vein Endothelial Cells; Humans; Indazoles; Pl | 2015 |